498 related articles for article (PubMed ID: 22210921)
1. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
[TBL] [Abstract][Full Text] [Related]
2. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
3. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
Maeda S; Shibata J; Fujiyama S; Tanaka M; Noumaru S; Sato K; Tomita K
Hepatogastroenterology; 2003; 50(51):809-13. PubMed ID: 12828090
[TBL] [Abstract][Full Text] [Related]
6. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.
Ikeda M; Arai Y; Park SJ; Takeuchi Y; Anai H; Kim JK; Inaba Y; Aramaki T; Kwon SH; Yamamoto S; Okusaka T; ;
J Vasc Interv Radiol; 2013 Apr; 24(4):490-500. PubMed ID: 23466316
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma.
Kawaoka T; Aikata H; Katamura Y; Takaki S; Waki K; Hiramatsu A; Takahashi S; Hieda M; Kakizawa H; Chayama K
J Vasc Interv Radiol; 2010 Aug; 21(8):1219-25. PubMed ID: 20619676
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
[TBL] [Abstract][Full Text] [Related]
12. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
Idée JM; Guiu B
Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
Ishida K; Hirooka M; Hiraoka A; Kumagi T; Uehara T; Hiasa Y; Horiike N; Onji M
Jpn J Clin Oncol; 2008 Sep; 38(9):596-603. PubMed ID: 18772170
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
15. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
17. [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].
Ikeda K; Okusaka T; Ikeda M; Morimoto M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):271-5. PubMed ID: 20154484
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma.
Takaki S; Sakaguchi H; Anai H; Tanaka T; Yamamoto K; Morimoto K; Nishiofuku H; Inoue M; Sueyoshi S; Nagata T; Hidaka T; Uchida H; Kichikawa K
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):544-54. PubMed ID: 21739345
[TBL] [Abstract][Full Text] [Related]
20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
